Close
VALOR Biogen’s Tofersen trial: a look at the open label extension data

VALOR Biogen’s Tofersen trial: a look at the open label extension data

Reading Time: 6 minutes The Motor Neurone Disease Association are pleased to discuss the additional results from the Biogen phase 3 clinical trial of Tofersen which were presented at the 20th European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) meeting in Edinburgh, Scotland, on the 1-3rd of June 2022. Tofersen is a type of potential treatment known…

Tofersen: antisense oligonucleotide drug shows promising results in Phase 1/2 trial

Tofersen: antisense oligonucleotide drug shows promising results in Phase 1/2 trial

Reading Time: 3 minutes A recent press release by the pharmaceutical company Biogen reported preliminary results from an ongoing clinical trial investigating a form of precision therapy in people with SOD1-related MND. This drug, known as tofersen, is now in the final stages of Phase 1/2 testing in centres across the world, including Sheffield in the UK. Tofersen is…